AbbVie (ABBV)

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience portfolios led the results.

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations.

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above analysts’ consensus estimates.

The company also raised its outlook for 2025, though noted that guidance hike doesn't include potential pharma sector tariffs.

U.S. stock futures continued to rise on Friday, following a three-day back-to-back winning streak in the regular session, amid growing earnings optimism and the easing of trade tensions between the U.S. and China.

U.S. stock futures are up Thursday night following three back-to-back days in the green during the regular session, amid growing earnings optimism and easing trade tensions.

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns.

The pharmaceutical giant has been a roller coaster over the past several months.